Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Vortioxetine 20 mg vs 2x10 mg in Healthy Japanese Adults
NCT03437564Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vortioxetine in major depressive disorder (MDD) (2 arms), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point and Maximum Plasma Concentration. Started Feb 2018; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03437564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437564.